RareSight™
Treatment Solution
- Drug mechanism-of-action backed by long-term clinical evidence
- Provides 6+ months of consistent drug release per injection
- Intravitreal administration widely used in clinical practice for age-related eye conditions and Retinopathy of Prematurity in infants
- Disruption of the underlying disease process
- Preservation of retinal structure (adhesion of retinal layers)
- Improvement in Visual Acuity
- Avoids daily compliance issues of eye drops and drug therapy
FUTURE STANDARD OF CARE FOR THE TREATMENT OF X-LINKED RETINOSCHISIS
What Are IRDs?
Inherited Retinal Diseases (IRDs) are a diverse group of rare genetic disorders that lead to progressive degeneration of the retina—the light-sensitive tissue at the back of the eye. These conditions can result in significant vision impairment and, in many cases, blindness.
Prevalence and Global Impact
IRDs collectively affect approximately 1 in 2,000 to 1 in 3,500 individuals worldwide, translating to an estimated 5.5 million people globally living with these conditions PNAS.
Genetic Diversity
- Over 250 genes have been identified as causative for IRDs, with many more likely undiscovered Lions Eye Institute.
- These conditions exhibit genetic heterogeneity, meaning that a single disease phenotype can result from mutations in different genes, complicating diagnosis and treatment development J&J Medical Cloud.
Diagnosis Challenges
- Diagnosing IRDs can be complex due to their genetic diversity and phenotypic overlap with other ocular conditions.
- Genetic testing is often required to confirm a diagnosis, but access to comprehensive genetic screening may be limited, especially in underserved regions PMC.
Impact on Quality of Life
- Studies have shown that patients with IRDs report lower quality of life scores, particularly in areas related to independent living, sensory function, and social relationships PMC.
- According to the Centers for Disease Control and Prevention (CDC), the estimated economic burden of vision loss and blindness in the United States is $134.2 billion annually.
Ophthalmology
Unmet Medical Need
- Currently, most IRDs have no approved drug treatments, leaving patients with limited options.
- The lack of effective therapies underscores a substantial unmet medical need, highlighting the importance of ongoing research and development in this field PMC.
How It's Work
We Take Care Senior Person Who Generally Alone
Daily Heart Checkup
Personalized Care Services
In-Home Health Care
Timely Food & Medicine
Deserves Our Best Services
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form.
Medical Checkup
Nursing Care
Residential Care
Health & Medical Care
Senior Citizen
Our mission is to provide accurate and timely medical diagnostic services to help you take control of your health.
Highest Level Expertise
Additional Services will Grow
97% Client Satisfaction
See & Experience A New Perspective Of Life
Our Protfolio
Caring for seniors is a labor of love and requires a special
What They Are Talking.
Approach
RareSight has deep expertise in pharmacology, drug discovery, clinical strategy and commercialization within ophthalmology and rare disease. We are exploring new treatment approaches for rare inherited retinal diseases, focusing on areas where no approved therapies exist. Partnering with physicians and drug delivery innovators, we are working to translate scientific insight, real-world evidence and clinical expertise into future treatment solutions.
Our goal is to design therapies that are not only effective but also practical in a pediatric setting with the mission of preventing children from losing vision early in life and helping them maintain sight throughout their lives.
Team
Carmen Caricchio
Founder & CEO
Carmen Caricchio is the CEO and Founder of RareSight, bringing more than 20 years of experience in the ophthalmic industry spanning product development, commercialization and strategic communications. Throughout the course of her career, she has brought more than 30 market-leading technologies in cornea, glaucoma, and retina into clinical practice.
Since 2018, Carmen has advised ophthalmic companies—from early-stage start-ups to public entities—on commercialization strategy, market evaluation, product development, clinical adoption, investor engagement and go-to-market planning. She also serves as an Expert-in-Residence at UCSF Innovation Ventures for the Department of Ophthalmology, where she evaluates new inventions and accelerates spin-out opportunities.
Prior to this, Carmen specialized in public relations, strategic communications and public affairs for the MedTech industry. She was the Founder/Principal of the award-winning CoActive Communications with offices in San Francisco, New York City and Sydney, Australia. During its 15-year span, her agency maintained a large portfolio of ophthalmic start-up clients, most of which were acquired by major industry strategics, due in part, to her agency’s steadfast media engagement, publication and podium strategies. Carmen was introduced to ophthalmology in 2002 as head of the West Coast office of Dorland Global, then the largest independently owned healthcare advertising agency in the U.S. Earlier in her career, Carmen headed up MCS WEST, the MedTech practice for New Jersey-based, MCS Health.
Carmen holds a BA in Organizational Leadership from the University of San Francisco with undergraduate studies at UC, Santa Cruz. She has received multiple awards from the Public Relations Society of America, PRCA Platinum Awards and the American Advertising Federation (ADDY) and is a 2024 National Science Foundation (NSF) grant recipient.
David Eveleth, PhD
Executive ChairmanDavid Eveleth, PhD, Executive Chairman of RareSight, has more than 30 years of commercial and scientific experience in ophthalmology, neuroscience and regenerative medicine. He currently serves on the board of several early-stage companies and consults for biotech and academic organizations.
As the founder and former CEO of Trefoil Therapeutics, Inc., a clinical-stage biotech company, David led the discovery of Trefoil’s lead investigational candidate, TTHX1114, for the treatment of corneal endothelial dystrophies and conditions via intracameral injection. At Trefoil, David raised approximately $50 million and advanced TTHX1114 through a successful Phase 2 clinical trial.
Previously, David spent 16 years at Pfizer where he led the Ophthalmology Medicines Development Group, a franchise that realized peak annual sales of $1.7 billion. During his tenure, he and his team achieved the approval and launch of Macugen for AMD and advanced Macugen’s Phase 3 program and regulatory submission for diabetic macular edema (outside the USA). He shaped Pfizer’s ophthalmology strategy through major reorganizations, a merger with Wyeth, and the development of a collaborative R&D model—ultimately tripling the franchise’s revenue.
David joined Pfizer through its acquisition of Pharmacia, where he was Senior and Executive Director. At Pharmacia, he led approvals for Xalatan as a first line agent, Xalacom and Xalatan/Xalatan Ease, and contributed to Healon and CeeOn/Tecnis product development. Prior to this, he held senior scientific and leadership roles at Bayer (Deputy Director and Licensing Officer) and Cortex Pharmaceuticals, where he worked as a Senior Scientist.
Throughout his career, David has been involved in or has led eight IND submissions, multiple new drug approvals and two medical device approvals. His leadership spans drug development, medical affairs, business development, and portfolio strategy. He was a Bank of America/Giannini Foundation fellow prior to joining industry.
David earned a Bachelor of Science in Biology from the University of Connecticut and his PhD in Biology from the University of California. He was a Bank of America/Giannini Foundation postdoctoral fellow prior to joining industry.
Achim Krauss, PhD
Chief Scientific OfficerAchim Krauss, PhD, FAOPT is Chief Scientific Officer at RareSight, responsible for overseeing non-clinical drug development and driving the Company’s scientific and technical strategy. He is also the Founder and Principal Consultant of Archer Ophthalmics, LLC, which provides support and consulting services for front-of-the-eye and retinal diseases to biotech and startup companies in ophthalmology.
Most recently, Achim was the Founder, CEO and President of AxeroVision, where he advanced two ophthalmic drug candidates - licensed from GSK - from preclinical development through IND filing and clinical proof-of-concept for the treatment of dry eye disease. In late 2022, AxeroVision was acquired by CS Pharmaceuticals, resulting in a successful exit.
Previously, Achim held various leadership positions at GSK, Pfizer and Allergan establishing a consistent track record in ophthalmic drug discovery and development. At GSK Ophthalmology, he was Director of Research, responsible for disease area strategy and programs in dry eye and glaucoma. At Pfizer, his roles included Head of Ocular Biology, Ophthalmology Therapeutic Area Leader, Ophthalmology Portfolio, Strategy and External Alliances Lead and member of the Global Discovery Management Committee. At Allergan, he was Principal Scientist with a primary focus on glaucoma research. Achim was a key contributor to the glaucoma drugs LUMIGAN® (also marketed as LATISSE® for cosmetic use) and VYZULTA™.
Achim is a Fellow of the Association for Ocular Pharmacology and Therapeutics where he served as President and on the Board of Directors for approximately 20 years. He also serves on the editorial board of the Journal for Ocular Pharmacology and Therapeutics. Achim is an author on more than 50 peer-reviewed scientific publications and an inventor on more than 20 granted patents. Achim earned a B.S. in Pharmacy and a Ph.D. (Dr. rer. nat.), graduating Magna cum Laude, from the University of Tübingen, Germany.
Michael Goldstein, MD
CAB Chair
Dr. Michael Goldstein advises RareSight on scientific and clinical strategy. Previously, Dr. Goldstein was the President and Chief Medical Officer of Aurion Biotech, where he led clinical strategy, development & operations medical affairs while overseeing the manufacturing & quality teams for the company’s first product candidate—a cell therapy for corneal edema secondary to endothelial dysfunction. Prior to joining Aurion, Dr. Goldstein served as President & Chief Medical Officer of Ocular Therapeutix, where he participated in development of longer-duration therapies for ophthalmic diseases. He was previously Chief Medical Officer at AGTC (Applied Genetic Technologies Corporation) and held senior leadership roles at Eleven Biotherapeutics, including Vice President of Clinical Research.
In academics, since 2002 he has been Co-Director of the Cornea & External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine. Earlier, he served as Director of Refractive Surgery Service at the University of Florida College of Medicine. He has published extensively and serves as reviewer for multiple ophthalmology journals.
Dr. Goldstein holds an M.D. from Northwestern University Feinberg School of Medicine; an M.B.A. from Northwestern’s Kellogg School of Management; and a B.A. in Political Economy from Williams College.
Reza Zadno
Corporate Strategy Advisor
Reza Zadno, PhD: Medtech Executive with 5 for 5 start-up exits via IPO or M&A
Operations:
- Cardiac Pathways: Electrophysiology, R&D; IPO+M&A Boston Sc.
- PercuSurge: Cardiology, Founder and CTO; M&A Medtronic
- Visiogen: Ophthalmology, Founder and CEO; M&A Abbott
- Avedro: Ophthalmology, CEO; IPO +M&A Glaukos
- Procept: Urology, CEO; IPO
- Took both Avedro and Procept Public in 2019 and 2021
- Grew Avedro revenue from 0 to $40M prior to Acquisition
- Grew Procept revenue from ~0 to $323M 2025 Guidance
- 5 Years Venture Partner at Interwest Partners and 3 years Advisor to Novartis
- Multiple rounds of private and public fund raising, Never a down round
- More than 100 Patents
- Work Experience in France, Belgium, UK and USA
Board Experience:
- CEO Director: Visiogen, Avedro, Procept
- American Academy of Ophthalmology: Board of Trustees
- Transcend Medical: Chairman, Glaucoma M&A Alcon
- Invuity: Audit Committee., Surgical Instruments IPO and M&A Stryker
- Carbylan: Audit Committee, Osteoarthritis, IPO and MA&A KalVista
- Oraya: Comp. Committee. Ophthalmology, M&A Zeiss
- Autonomic Technologies: Cluster Headache
- CVRX: Hypertension and Heart failure, IPO
- Benvenue: Spine ( Board Observer)
- Obalon: Obesity (Board Observer)
Licensing:
- Personal Patent in Mitral Valve Repair licensed to eValve now Abbott
- Personal Patent in AAA licensed to Aneuryx now Medtronic
- Personal Patent in COPD licensed to Emphasys now Pulmonx
Education:
PhD in Mechanical Properties of Materials, Ecole Nationale Superieure des Mines de Paris
Jim Sergi
CMC, GMP and Regulatory Advisor
Jim Sergi is the Founder and the President of QNova LifeSciences, a global regulatory consulting firm
providing fully integrated, specialized regulatory and clinical services for pharmaceutical and medical
device companies from discovery to commercialization. Prior to this role, Jim was the founder and
managing partner of Bay Tower Capital, a life sciences merchant bank and the co-founder and CEO of
ProED Communications, a healthcare services and drug development company.
Jim has been responsible for over 85 successful NDA/BLA approvals and over 250 medical device
approvals. His academic and medical experience includes Director of Experimental Therapeutics at the
Cleveland Clinic Cancer Center, Associate Professor of Medical-Surgical Nursing at the Case Western
Reserve University. Lecturer for Oncology at Cleveland State University and Adjunct Faculty and Lecturer
for biotechnology at Georgetown University and John Hopkins University Graduate Schools. He has
authored over 50 peer reviewed publications and has numerous issued patents. Jim serves a scientific
reviewer for the NIH SBIR/STTR Commercial Readiness Program, as well as a mentor to the NIH/NHLBI
and the NIH Larta FeedForward programs.
Jim also serves as a scientific advisor and board member to numerous nonprofits, corporations, private
equity and venture backed investment firms, including Defta Partners. Jim has an undergraduate degree
in nursing from Edinboro University of Pennsylvania and a graduate degree from the University of Akron.
Jim also serves as the GP of QNova Capital, a venture formation life sciences fund to accelerate and de-
risk breakthrough drugs and medical devices to transform patient lives.
Latest News
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
FORT WORTH, Texas, MELBOURNE, Australia, and MENLO PARK, California — November 5, 2025 — PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ophthalmology-focused life sciences company committed to advancing therapies for inherited retinal diseases (IRDs), today announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments.
The research collaboration agreement, leveraging PolyActiva’s proprietary PREZIA™ platform, will offer first-of-its-kind, new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions. Administered intravitreally, the approach will deliver sustained-release, zero-order treatment directly to the retina, requiring no patient administration—a key benefit for children and their caregivers.
Contact Us
RareSight™
Have questions or need more information? Send us a note and one of our team members will respond as soon as possible.
